EUVIMEDEUVIMED entdecken
Crossref

Tacrolimus associated with lower infection risk compared to conventional immunosuppressants in systemic lupus erythematosus: real-world evidence

Hanze Zhu, Ziyi Jin, Yong Luo, Xiaojun Tang, Wei Shen, Huayong Zhang, Dandan Wang, Xuebing Feng, Lingyun Sun

Clinical Rheumatology · 2026

DOI: 10.1007/s10067-025-07772-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Rheumatology, 2026. Verfasst von Hanze Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, School of Medicine, Nanjing Drum Tower Hospital, Southeast University, Nanjing, 210009, People's Republic …. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Immunosuppressive Agents, Tacrolimus, Infections. Die Arbeit nennt 25 Literaturangaben. Gefördert von: the Key Program of the National Natural Science Foundation of China, Medical Science and Technology Development Foundation, Nanjing Municipality Health Bureau, Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Infection remains a leading cause of mortality in systemic lupus erythematosus (SLE), this study aimed to evaluate the impact of tacrolimus (TAC) use on infection risk in SLE patients. METHODS: A nested case-control study analyzed 3,176 SLE patients (1,509 infection cases; 1,667 controls) from SLE cohort (2010-2021). TAC exposure was defined as ≥ 30 consecutive days of use within 12 months preceding infection diagnosis or index date. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for associations between TAC use and infections risk. Drug combination effects of TAC was analyzed with cyclophosphamide (CYC), mycophenolate mofetil (MMF), hydroxychloroquine (HCQ), and glucocorticoids. RESULTS: After controlling for confounders (adjusted OR, 95% CI), TAC use was associated with a 60% lower overall infection risk versus other conventional immunosuppressants (0.40, 0.30-0.51), with stronger reductions in bacterial (0.50, 0.37-0.67) and skin/mucosal infections (0.30, 0.13-0.72). Significantly lower risks were observed at lower dosages (≤ 2 mg/d, OR 0.34, 0.24-0.47) and with prolonged use (> 365 days, OR 0.29, 0.19-0.46). Subgroup analyses confirmed enhanced protection in high-risk populations, such as severe disease activity (SLEDAI-2 K > 12, OR 0.32, 0.22-0.46) and CNS involvement (0.25, 0.09-0.71). TAC-HCQ co-therapy reduced infection risk (0.37, 0.27-0.52); separately, TAC counteracted glucocorticoid-associated risk (0.48, 0.30-0.77), and attenuated CYC/MMF-related risk (1.31, 0.83-2.06 vs. 4.25, 2.53-7.13 for CYC-MMF combinations). CONCLUSIONS: TAC offers superior infection prevention versus other conventional immunosuppressants in SLE, advocating for TAC-centered regimens to optimize risk-benefit profiles. Key Points • TAC use was associated with lower infection risk compared to other conventional immunosuppressants, particularly for bacterial infections and skin/mucosal infections. • Dose-response relationships were identified between both TAC dosage and duration of use and lower infection risk in SLE patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicImmunosuppressive AgentsTacrolimusInfectionsHumansFemaleMaleAdultCase-Control StudiesMiddle AgedDrug Therapy, CombinationMycophenolic AcidGlucocorticoidsHydroxychloroquineCyclophosphamide

Stichwörter der Autor:innen

Dose–response relationship, drugImmunosuppressive agentsInfectionSystemic lupus erythematosus (SLE)Tacrolimus (TAC)

Substanzen

Immunosuppressive AgentsTacrolimusMycophenolic AcidGlucocorticoidsHydroxychloroquineCyclophosphamide

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, School of Medicine, Nanjing Drum Tower Hospital, Southeast University, Nanjing, 210009, People's Republic of China.
  • Department of Rheumatology and Immunology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, People's Republic of China. jzy-327@163.com.
  • Rheumatology Medical Center and Stem Cell Intervention Center, Department of Rheumatology and Immunology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, People's…
  • Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210008, People's Republic of China.
  • Department of Rheumatology and Immunology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, People's Republic of China.
  • Department of Rheumatology and Immunology, School of Medicine, Nanjing Drum Tower Hospital, Southeast University, Nanjing, 210009, People's Republic of China. lingyunsun@nju.edu.cn.

Förderung

  • the Key Program of the National Natural Science Foundation of China
  • Medical Science and Technology Development Foundation, Nanjing Municipality Health Bureau
  • Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University

Zitieren

APA

Zhu, H., Jin, Z., Luo, Y., Tang, X., Shen, W., Zhang, H., Wang, D., Feng, X., & Sun, L. (2026). Tacrolimus associated with lower infection risk compared to conventional immunosuppressants in systemic lupus erythematosus: real-world evidence. Clinical Rheumatology. https://doi.org/10.1007/s10067-025-07772-7

Vancouver

Zhu H, Jin Z, Luo Y, Tang X, Shen W, Zhang H, et al. Tacrolimus associated with lower infection risk compared to conventional immunosuppressants in systemic lupus erythematosus: real-world evidence. Clinical Rheumatology. 2026. doi:10.1007/s10067-025-07772-7

BibTeX
@article{Zhu2026,
  author = {Zhu, Hanze and Jin, Ziyi and Luo, Yong and Tang, Xiaojun and Shen, Wei and Zhang, Huayong and Wang, Dandan and Feng, Xuebing and Sun, Lingyun},
  title = {Tacrolimus associated with lower infection risk compared to conventional immunosuppressants in systemic lupus erythematosus: real-world evidence},
  journal = {Clinical Rheumatology},
  year = {2026},
  doi = {10.1007/s10067-025-07772-7}
}
Kostenlos starten →